The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
2 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $698,285 in first-year total cost, median $349,143.
Most frequent study sections
- Special Emphasis Panel[ZRG1 ETTN-A (15)]1
- Special Emphasis Panel[ZRG1 ETTN-P (13)]1
Most frequent institutions
- NEMALIFE INC.1
- NEMAMETRIX, INC.1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2021 | High-throughput testing of anti-aging and FDA approved drugs in genetically diverse invertebrate Alzheimer's models1R43AG071142-01 | TOTH, MARTON | NEMALIFE INC., TX | $348,285 | ZRG1 |
| 2018 | Testing Lifespan/Healthspan Pharmacological Interventions in Humanized C. elegans Knock-In Models of Dementia1R43AG061978-01 | BROCK, TRISHAHART, ANNE CHURCHHOPKINS, CHRISTOPHER EMCCORMICK, KATHRYN E | NEMAMETRIX, INC., OR | $350,000 | ZRG1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.